Last reviewed · How we verify
PA9159 Inhalation aerosol, 120 μg one day treatment — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PA9159 Inhalation aerosol, 120 μg one day treatment (PA9159 Inhalation aerosol, 120 μg one day treatment) — Anhui Palo Alto Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PA9159 Inhalation aerosol, 120 μg one day treatment TARGET | PA9159 Inhalation aerosol, 120 μg one day treatment | Anhui Palo Alto Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PA9159 Inhalation aerosol, 120 μg one day treatment CI watch — RSS
- PA9159 Inhalation aerosol, 120 μg one day treatment CI watch — Atom
- PA9159 Inhalation aerosol, 120 μg one day treatment CI watch — JSON
- PA9159 Inhalation aerosol, 120 μg one day treatment alone — RSS
Cite this brief
Drug Landscape (2026). PA9159 Inhalation aerosol, 120 μg one day treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/pa9159-inhalation-aerosol-120-g-one-day-treatment. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab